Human cathelicidin LL-37-derived peptide IG-19 confers protection in a murine model of collagen-induced arthritis

Molecular Immunology

Volumn 57, Issue 2, 2014, Pages 86-92

  Chow, Leola N Y ^a   Choi, Ka Yee Grace ^a,b   Piyadasa, Hadeesha ^a,b   Bossert, Maike ^b   Uzonna, Jude ^b   Klonisch, Thomas ^b   Mookherjee, Neeloffer ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cathelicidin; Chronic inflammation; Collagen induced arthritis; Host defence peptides; LL 37; Rheumatoid arthritis

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLLAGEN; IG 19; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; HOST RESISTANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

CATHELICIDIN; CHRONIC INFLAMMATION; COLLAGEN-INDUCED ARTHRITIS; HOST DEFENCE PEPTIDES; LL-37; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMICROBIAL CATIONIC PEPTIDES; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN; CYTOKINES; DISEASE MODELS, ANIMAL; JOINTS; MALE; MICE; MICE, INBRED DBA;

EID: 84884959307     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.08.011     Document Type: Article

References (52)

1. Achtman A.H., Pilat S., Law C.W., Lynn D.J., Janot L., Mayer M.L., Ma S., Kindrachuk J., Finlay B.B., Brinkman F.S., et al. Effective adjunctive therapy by an innate defense regulatory Peptide in a preclinical model of severe malaria. Science Translational Medicine 2012, 4:135ra64.
2. Altomonte L., Zoli A., Mirone L., Scolieri P., Magaro M. Serum levels of interleukin-1b, tumor necrosis factor-a and interleukin-2 in rheumatoid arthritis correlation with disease activity. Clinical Rheumatology 1992, 11:202-205.
3. Asquith D.L., Mclnnes I.B. Emerging cytokine targets in rheumatoid arthritis. Current Opinion in Rheumatology 2007, 19:246-251.
4. Bevaart L., Vervoordeldonk M.J., Tak P.P. Collagen-induced arthritis in mice. Methods in Molecular Biology 2010, 602:181-192.
5. Bommarius B., Jenssen H., Elliott M., Kindrachuk J., Pasupuleti M., Gieren H., Jaeger K.E., Hancock R.E., Kalman D. Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 2010, 31:1957-1965.
6. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmunity Reviews 2005, 4:162-170.
7. Bowdish D.M., Davidson D.J., Lau Y.E., Lee K., Scott M.G., Hancock R.E. Impact of LL-37 on anti-infective immunity. Journal of Leukocyte Biology 2005, 77:451-459.
8. Brahn E., Peacock D.J., Banquerigo M.L., Liu D.Y. Effects of tumor necrosis factor alpha (TNF-alpha) on collagen arthritis. Lymphokine Cytokine Research 1992, 11:253-256.
9. Brand D.D., Latham K.A., Rosloniec E.F. Collagen-induced arthritis. Nature Protocols 2007, 2:1269-1275.
10. Burton M.F., Steel P.G. The chemistry and biology of LL-37. Natural Products Reports 2009, 26:1572-1584.
11. Cherkasov A., Hilpert K., Jenssen H., Fjell C.D., Waldbrook M., Mullaly S.C., Volkmer R., Hancock R.E. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chemical Biology 2009, 4:65-74.
12. Cho Y.G., Cho M.L., Min S.Y., Kim H.Y. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmunity Reviews 2007, 7:65-70.
13. Choi K.Y., Mookherjee N. Multiple immune-modulatory functions of cathelicidin host defense peptides. Frontiers in Immunology 2012, 3:149.
14. Chromek M., Slamova Z., Bergman P., Kovacs L., Podracka L., Ehren I., Hokfelt T., Gudmundsson G.H., Gallo R.L., Agerberth B., et al. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nature Medicine 2006, 12:636-641.
15. Cirioni O., Giacometti A., Ghiselli R., Bergnach C., Orlando F., Silvestri C., Mocchegiani F., Licci A., Skerlavaj B., Rocchi M., et al. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrobial Agents and Chemotherapy 2006, 50:1672-1679.
16. 1. The Journal of Immunology 1988, 141:1958-1962.
17. Cooper W.O., Fava R.A., Gate C.A., Cremer M.A., Townes A.S. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumour necrosis factor or transforming growth factor-beta. Clinical Experimental Immunology 1992, 89:244-250.
18. 2 production by human synovial cells and dermal fibroblasts. Journal of Experimental Medicine 1985, 162:2163-2168.
19. Dombrowski Y., Peric M., Koglin S., Kammerbauer C., Goss C., Anz D., Simanski M., Glaser R., Harder J., Hornung V., et al. Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions. Science Translational Medicine 2011, 3:82ra38.
20. Feldman M., Maini R.N. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nature Medicine 2003, 9:1245-1250.
21. Gabriel S.E. The epidemiology of rheumatoid arthritis. Rheumatic Disease Clinics of North America 2001, 27:269-281.
22. Galligan C.L., Siminovitch K.A., Keystone E.C., Bykerk V., Perez O.D., Fish E.N. Fibrocyte activation in rheumatoid arthritis. Rheumatology 2010, 49:640-651.
23. Gartlehner G., Hansen R.A., Jonas B.L., Thieda P., Lohr K.N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systemic review and metaanalysis. The Journal of Rheumatology 2006, 33:2398-2408.
24. Hegen M., Keith J.C., Collins M., Nickerson-Nutter C.L. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Annals of the Rheumatic Diseases 2008, 67:1505-1515.
25. Holmdahl R., Klareskog L., Andersson M., Hansen C. High antibody response to autologous type II collagen is restricted to H-2q. Immunogenetics 1986, 24:84-89.
26. Hutamekalin P., Saito T., Yamaki K., Mizutani N., Brand D.D., Waritani T., Terato K., Yoshino S. Collagen antibody-induced arthritis in mice: development of a new arthritogenic 5-clone cocktail of monoclonal anti-type II collagen antibodies. Journal of Immunological Methods 2009, 343:49-55.
27. Iyer S.S., Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Critical Reviews in Immunology 2012, 32:23-63.
28. Jo E.K. Innate immunity to mycobacteria: vitamin D and autophagy. Cellular Microbiology 2010, 12:1026-1035.
29. Kanda N., Ishikawa T., Kamata M., Tada Y., Watanabe S. Increased serum leucine, leucine-37 levels in psoriasis: positive and negative feedback loops of leucine, leucine-37 and pro- or anti-inflammatory cytokines. Human Immunology 2010, 71:1161-1171.
30. Mayer M.L., Blohmke C.J., Falsafi R., Fjell C.D., Madera L., Turvey S.E., Hancock R.E. Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. Journal of Immunology 2013, 190:1227-1238.
31. Molhoek E.M., den Hertog A.L., de Vries A.M., Nazmi K., Veerman E.C., Hartgers F.C., Yazdanbakhsh M., Bikker F.J., van der Kleij D. Structure-function relationship of the human antimicrobial peptide LL-37 and LL-37 fragments in the modulation of TLR responses. Biological Chemistry 2009, 390:295-303.
32. Mookherjee N., Brown K.L., Bowdish D.M.E., Doria S., Falsafi R., Hokamp K., Roche F.M., Mu R., Doho G.H., Pistolic J., et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. The Journal of Immunology 2006, 176:2455-2464.
33. Mookherjee N., Wilson H.L., Doria S., Popowych Y., Falsafi R., Yu J.J., Li Y., Veatch S., Roche F.M., Brown K.L., et al. Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. Journal of Leukocyte Biology 2006, 80:1563-1574.
34. Mookherjee N., Hamill P., Gardy J., Blimkie D., Falsafi R., Chikatamarla A., Arenillas D.J., Doria S., Kollmann T.R., Hancock R.E. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Molecular BioSystems 2009, 5:483-496.
35. Morioka Y., Yamasaki K., Leung D., Gallo R.L. Cathelicidin antimicrobial peptides inhibit hyaluronan-induced cytokine release and modulate chronic allergic dermatitis. Journal of Immunology 2008, 181:3915-3922.
36. Nandakumar K.S., Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. Journal of Immunological Methods 2005, 304:126-136.
37. Nijnik A., Madera L., Ma S., Waldbrook M., Elliott M.R., Easton D.M., Mayer M.L., Mullaly S.C., Kindrachuk J., Jenssen H., et al. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. Journal of Immunology 2010, 184:2539-2550.
38. Nishikawa M., Myoui A., Tomita T., Takahi K., Nampei A., Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis and Rheumatism 2003, 48:2670-2681.
39. Nizet V., Ohtake T., Lauth X., Trowbridge J., Rudisill J., Dorschner R.A., Pestonjamasp V., Piraino J., Huttner K., Gallo R.L. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001, 414:454-457.
40. Pena O.M., Afacan N., Pistolic J., Chen C., Madera L., Falsafi R., Fjell C.D., Hancock R.E. Synthetic cationic peptide IDR-1018 modulates human macrophage differentiation. PLOS ONE 2013, 8:e52449.
41. Saklatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986, 322:547-549.
42. Scott M.G., Dullaghan E., Mookherjee N., Glavas N., Waldbrook M., Thompson A., Wang A., Lee K., Doria S., Hamill P., et al. An anti-infective peptide that selectively modulates the innate immune response. Nature Biotechnology 2007, 25:465-472.
43. Sun J., Jia Y., Li R., Guo J., Sun X., Liu Y., Li Y., Yao H., Liu X., Zhao J., et al. Altered influenza virus haemagglutinin (HA)-derived peptide is potent therapy for CIA by inducing Th1 to Th2 shift. Cellular & Molecular Immunology 2011, 8:348-358.
44. Tai E.K., Wu W.K., Wong H.P., Lam E.K., Yu L., Cho C.H. A new role for cathelicidin in ulcerative colitis in mice. Experimental Biology and Medicine (Maywood, NJ) 2007, 232:799-808.
45. Torossian A., Gurschi E., Bals R., Vassiliou T., Wulf H.F., Bauhofer A. Effects of the antimicrobial peptide LL-37 and hyperthermic preconditioning in septic rats. Anesthesiology 2007, 107:437-441.
46. Turner-Brannen E., Choi K.Y., Lippert D.N., Cortens J.P., Hancock R.E., El-Gabalawy H., Mookherjee N. Modulation of interleukin-1beta-induced inflammatory responses by a synthetic cationic innate defence regulator peptide, IDR-1002, in synovial fibroblasts. Arthritis Research and Therapy 2011, 13:R129.
47. van der Does A.M., Beekhuizen H., Ravensbergen B., Vos T., Ottenhoff T.H., van Dissel J.T., Drijfhout J.W., Hiemstra P.S., Nibbering P.H. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. Journal of Immunology 2010, 185:1442-1449.
48. van Holten J., Reedquist K., Sattonet-Roche P., Smeets T.J., Plater-Zyberk C., Vervoordeldonk M.J., Tak P.P. Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Research and Therapy 2004, 6:R239-R249.
49. Vandamme D., Landuyt B., Luyten W., Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology 2012, 280:22-35.
50. Wieczorek M., Jenssen H., Kindrachuk J., Scott W.R., Elliott M., Hilpert K., Cheng J.T., Hancock R.E., Straus S.K. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chemistry and Biology 2010, 17:970-980.
51. Winthrop K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nature Clinical Practice Rheumatology 2006, 2:602-610.
52. Yeung A.T., Gellatly S.L., Hancock R.E. Multifunctional cationic host defence peptides and their clinical applications. Cellular and Molecular Life Sciences 2011, 68:2161-2176.